【摘要】：目的：1.通過對(duì)應(yīng)用中醫(yī)補(bǔ)腎強(qiáng)督法治療強(qiáng)直性脊柱炎(ankylosing spondylitis, AS)的療效和安全性進(jìn)行文獻(xiàn)的系統(tǒng)評(píng)價(jià)及meta分析,為補(bǔ)腎強(qiáng)督法治療AS提供初級(jí)循證醫(yī)學(xué)證據(jù)。2.采用隨機(jī)、對(duì)照、前瞻性臨床研究,客觀評(píng)價(jià)中醫(yī)補(bǔ)腎強(qiáng)督法綜合方案治療AS在關(guān)節(jié)功能狀態(tài)及影像學(xué)方面的臨床療效,揭示其抗骨化潛能,并為后期大樣本、多中心的隨機(jī)對(duì)照研究提供參考。3.以Connexin43 (Cx43)為靶點(diǎn),研究補(bǔ)腎強(qiáng)督方藥對(duì)體外培養(yǎng)的大鼠成纖維細(xì)胞增殖及成骨分化的影響,初步探討補(bǔ)腎強(qiáng)督法抗AS異位骨化的機(jī)制,為其臨床療效提供科學(xué)證據(jù)。方法：1.系統(tǒng)評(píng)價(jià)系統(tǒng)評(píng)價(jià)近30年間發(fā)表的應(yīng)用補(bǔ)腎強(qiáng)督法治療AS的臨床隨機(jī)對(duì)照研究的文獻(xiàn),通過分析文獻(xiàn)確定檢索主題詞,計(jì)算機(jī)檢索PubMed (1985/2015-5)、Embase (1985/2015-5)、ScienceDirect (1985/2015-5)、CBM (1985/2015-5)、VIP (1985/2015-5)、CNKI (1985/2015-5)和WANFANG(1985/2015-5),使用Note express V3.0.2.6367進(jìn)行文獻(xiàn)數(shù)據(jù)庫(kù)的管理,通過Excel進(jìn)行數(shù)據(jù)的提取,采用Cochrane Review Manager 5.2進(jìn)行偏倚風(fēng)險(xiǎn)評(píng)價(jià)和Meta分析。2.臨床研究納入腎虛督寒證AS患者30例,隨機(jī)分為中醫(yī)試驗(yàn)組及西醫(yī)對(duì)照組,兩組各15例,均采用功能鍛煉作為基礎(chǔ)治療,試驗(yàn)組服用補(bǔ)腎強(qiáng)督治僂湯加減,并聯(lián)合督灸,對(duì)照組服用塞來昔布,療程均為48周,采用ASAS工作組推薦的基于CRP的AS疾病活動(dòng)指數(shù)(ASDAS-CRP)為主要療效評(píng)價(jià)標(biāo)準(zhǔn),并通過巴氏AS功能指數(shù)(BASFI),巴氏AS測(cè)量指數(shù)(BASMI)和胸廓活動(dòng)度,AS生活質(zhì)量問卷(ASQoL)及骶髂關(guān)節(jié)核磁(MRI)評(píng)價(jià)補(bǔ)腎強(qiáng)督綜合方案治療AS在關(guān)節(jié)功能狀態(tài)及影像學(xué)方面的臨床療效,初步探討其抗骨化潛能。3.實(shí)驗(yàn)研究以體外培養(yǎng)的大鼠髖關(guān)節(jié)周圍韌帶成纖維細(xì)胞為研究對(duì)象,采用MTS法觀察補(bǔ)腎強(qiáng)督治僂湯對(duì)成纖維細(xì)胞增殖的影響,并采用免疫印跡(WB)法探究補(bǔ)腎強(qiáng)督治僂湯對(duì)成纖維細(xì)胞成骨標(biāo)志蛋白及Cx43蛋白表達(dá)的影響。結(jié)果：1.系統(tǒng)評(píng)價(jià)初檢出相關(guān)文獻(xiàn)923篇,排除重復(fù)文獻(xiàn)214篇,排除非隨機(jī)對(duì)照試驗(yàn)、動(dòng)物試驗(yàn)、綜述、經(jīng)驗(yàn)論述673篇,排除研究設(shè)計(jì)、干預(yù)措施、結(jié)局指標(biāo)等不符合納入／排除標(biāo)準(zhǔn)的文獻(xiàn)23篇,納入可分析文獻(xiàn)13篇,共972例病例。結(jié)果顯示,以補(bǔ)腎強(qiáng)督法治療方案/基于補(bǔ)腎強(qiáng)督法的中西醫(yī)結(jié)合治療方案治療AS, AS療效評(píng)價(jià)標(biāo)準(zhǔn)20(ASAS20)達(dá)標(biāo)率、中醫(yī)證候改善率、血沉(ESR)、疼痛視覺模擬評(píng)分法(Visual Analogue Scale/Score, VAS)、腰椎活動(dòng)度(Schober)均高于西醫(yī)治療組(RR= 1.19 [1.03, 1.24],Z=2.37,P=0.02; RR= 1.17 [1.07,1.28],Z=3.44,P=0.0006; MD=-0.62 [-1.08,-0.17], Z=2.67, P=0.008; MD=-14.23 [-22.58,-5.88], Z=3.34, P=0.0008; MD=0.36 [0.20,0.53], Z=4.41, P0.0001)。2.臨床研究中醫(yī)補(bǔ)腎強(qiáng)督法綜合方案和西醫(yī)綜合方案均可顯著降低AS患者ASDAS-CRP、 BASFI、ASQoL并改善骶髂關(guān)節(jié)骨髓水腫評(píng)分(SPARCC評(píng)分)(P0.05),但對(duì)BASMI和胸廓活動(dòng)度無明顯改善作用(P0.05),兩組差異無顯著性意義(P0.05)；在改善AS關(guān)節(jié)面硬化、侵蝕及骨贅的形成情況的骨質(zhì)病變方面中醫(yī)試驗(yàn)組優(yōu)于西醫(yī)對(duì)照組(P0.05)。3.實(shí)驗(yàn)研究補(bǔ)腎強(qiáng)督方藥對(duì)大鼠成纖維細(xì)胞增殖具有抑制作用,且呈現(xiàn)出一定的濃度依賴性,隨藥物濃度升高而抑制作用增強(qiáng),500μg/ml的補(bǔ)腎強(qiáng)督方藥對(duì)大鼠成纖維細(xì)胞增殖的抑制率達(dá)(18.791±4.637)%(P0.001)；補(bǔ)腎強(qiáng)督方藥以及塞來昔布可同時(shí)下調(diào)成纖維細(xì)胞核心結(jié)合因子(Core Binding Factorα1, Cbfα1)、Cx43及磷酸化的Cx43(pCx43)蛋白的表達(dá)(P0.05或P0.001),兩組比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論：1.中醫(yī)補(bǔ)腎強(qiáng)督法治療方案/基于補(bǔ)腎強(qiáng)督的中西醫(yī)結(jié)合治療方案治療AS與單純西醫(yī)治療AS比較,療效較好,為中醫(yī)補(bǔ)腎強(qiáng)督法應(yīng)用于AS治療提供了有力證據(jù)。2.補(bǔ)腎強(qiáng)督法綜合方案治療AS可有效改善患者關(guān)節(jié)功能狀態(tài),糾正患者骶髂關(guān)節(jié)骨髓水腫,且在骨質(zhì)改善上展現(xiàn)出較西醫(yī)對(duì)照組更好的療效,提示中醫(yī)補(bǔ)腎強(qiáng)督法綜合方案治療AS療效肯定,且可能在抗骨化作用上具有一定潛能和優(yōu)勢(shì)。3.補(bǔ)腎強(qiáng)督法可能通過抑制成纖維細(xì)胞的增殖并調(diào)節(jié)Cx43半通道而抑制韌帶成纖維細(xì)胞的成骨分化,起到抗AS骨化、延緩AS骨質(zhì)病變的作用。
[Abstract]:Objective: 1. through the systematic evaluation and meta analysis of the curative effect and safety of ankylosing spondylitis (AS) in the treatment of ankylosing spondylitis (AS) by using Chinese traditional Chinese medicine for tonifying kidney and governor, to provide primary evidence-based evidence for the treatment of AS by reinforcing kidney and governor method,.2. is random, contrast, forward-looking clinical study and objective evaluation of traditional Chinese medicine. The therapeutic effect of AS on joint functional status and imaging, and to reveal its anti ossification potential, and to provide reference.3. to Connexin43 (Cx43) as a target for large sample and multi center randomized controlled study, to investigate the effect of tonifying kidney and governor prescription drugs on the proliferation and osteogenic differentiation of rat fibroblasts cultured in vitro. To discuss the mechanism of reinforcing kidney and governor method against AS heterotopic ossification and providing scientific evidence for its clinical efficacy. Methods: 1. systematic evaluation system was used to evaluate the literature of the clinical randomized controlled study on the treatment of AS by reinforcing kidney and governor method in the last 30 years. Through the analysis of the literature, the subject words were retrieved, and the computing machine retrieved PubMed (1985/2015-5), Embase (1985/2015-5). ScienceDirect (1985/2015-5), CBM (1985/2015-5), VIP (1985/2015-5), CNKI (1985/2015-5) and WANFANG (1985/2015-5), use Note express to carry out the management of the literature database. 30 AS patients with cold syndrome were randomly divided into the traditional Chinese medicine test group and the western medicine control group, 15 cases in each of the two groups, all with functional exercise as the basic treatment. The test group took tonifying kidney and Qiang Du Zhi Tang Decoction plus subtraction, and the control group was treated with celecoxib for 48 weeks, using the CRP based AS disease activity index recommended by the ASAS working group (ASDAS-CRP For the main therapeutic evaluation criteria, and through the pasteurized AS function index (BASFI), the pasteurized AS measurement index (BASMI) and the thoracic activity degree, the AS life quality questionnaire (ASQoL) and the sacroiliac joint NMR (MRI), the clinical effect of the combination of the kidney and the strong governor (MRI) for the treatment of AS in the functional state and image of the joint was evaluated, and its anti ossification potential.3. experiment was preliminarily discussed. The effect of tonifying kidney and Qiang Du Zhi Zhi Decoction on fibroblast proliferation was studied by MTS method, and the effect of invigorating kidney and Qiang Du Zhi Zhi Decoction on the expression of osteoblast marker protein and Cx43 protein in fibroblasts was investigated by WB method. Results: 1. 923 articles were first detected, 214 articles were excluded, non randomized controlled trials, animal tests, review, 673 experiences, 23 articles that were excluded from the inclusion / exclusion criteria were excluded from research design, intervention measures and outcome indicators, including 13 articles and 972 cases. The combination of Chinese and Western medicine based on reinforcing the kidney and strengthening the kidney was treated for the treatment of AS, the standard 20 (ASAS20), the improvement rate of TCM syndrome, the ESR, the Visual Analogue Scale/Score, VAS, and the lumbar activity (Schober) higher than that of the western medicine group (RR= 1.19 [1.03, 1.24], VAS, 1.17). .28], Z=3.44, P=0.0006; MD=-0.62 [-1.08, -0.17], Z=2.67, P=0.008; MD=-14.23 [-22.58, -5.88], Z=3.34. (SPARCC score) (P0.05), but no significant improvement on BASMI and thoracic activity (P0.05), there was no significant difference between the two groups (P0.05). In the improvement of AS joint sclerosis, erosion and osteophyte formation, the traditional Chinese medicine test group was superior to the western medicine group (P0.05).3. experiment to study the fibroblast fineness of tonifying kidney and strong governor prescription drugs to rats. Cell proliferation had a inhibitory effect, and showed a certain concentration dependence. The inhibitory effect was enhanced with the increase of drug concentration. The inhibitory rate of 500 g/ml tonifying kidney strong governor on the proliferation of rat fibroblasts was (18.791 + 4.637)% (P0.001), and celecoxib could reduce the core binding factor of fibroblasts at the same time (Core The expression of Binding Factor alpha 1, Cbf alpha 1), Cx43 and phosphorylated Cx43 (pCx43) protein (P0.05 or P0.001), the difference between the two groups was not statistically significant (P0.05). Conclusion: 1. Chinese traditional Chinese medicine for tonifying kidney and strong governor method / based on the combination of traditional Chinese and Western medicine treatment scheme based on reinforcing kidney and governor is compared with pure western medicine for AS, and the curative effect is better, and it is the strengthening of kidney in traditional Chinese medicine. The application of the governor method to the treatment of AS provides strong evidence for the combination of.2. kidney and strong governor method in the treatment of AS, which can effectively improve the state of the joint function, correct the bone marrow edema of the sacroiliac joint, and show a better curative effect on the bone improvement than the western medicine control group. There is a certain potential and advantage in the ossification effect of.3., which may inhibit the proliferation of fibroblasts and regulate the Cx43 semi channel to inhibit the osteogenic differentiation of the ligament fibroblasts, and play an anti AS ossification and delay the effect of AS osteogenesis.
【學(xué)位授予單位】：廣州中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 譚永霞;強(qiáng)直性脊柱炎誤診1例[J];中國(guó)綜合臨床;2000年03期

2 李軍,陳列;手法配合中藥治療強(qiáng)直性脊柱炎9例臨床報(bào)導(dǎo)[J];甘肅中醫(yī)學(xué)院學(xué)報(bào);2000年03期

3 李朝暉,姜永慶;中西醫(yī)結(jié)合治療強(qiáng)直性脊柱炎臨床體會(huì)[J];黑龍江醫(yī)學(xué);2000年12期

4 徐翠華;強(qiáng)直性脊柱炎12例誤診分析[J];遼寧醫(yī)學(xué)雜志;2000年01期

5 宋偉東;女性強(qiáng)直性脊柱炎誤診一例[J];中國(guó)療養(yǎng)醫(yī)學(xué);2000年01期

6 楊清銳,遇曉,張?jiān)闯?強(qiáng)直性脊柱炎的治療[J];山東醫(yī)藥;2001年09期

7 龔衛(wèi)娟,范麗安;強(qiáng)直性脊柱炎發(fā)病的遺傳因素研究進(jìn)展[J];國(guó)外醫(yī)學(xué).遺傳學(xué)分冊(cè);2001年01期

8 葉新生;三兄弟同患強(qiáng)直性脊柱炎報(bào)告[J];海南醫(yī)學(xué);2001年04期

9 潘建玲,于威,蒲米娜;強(qiáng)直性脊柱炎合并急性早幼粒細(xì)胞白血病1例[J];黑龍江醫(yī)學(xué);2001年08期

10 信素英,樊愛華,陳永漢;中西醫(yī)結(jié)合治療強(qiáng)直性脊柱炎50例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2001年07期

相關(guān)會(huì)議論文 前10條

1 張?jiān)闯?楊清銳;遇曉;張春玲;陳立輝;;強(qiáng)直性脊柱炎的治療[A];中國(guó)免疫學(xué)會(huì)第四屆學(xué)術(shù)大會(huì)會(huì)議議程及論文摘要集[C];2002年

2 馬麗;;強(qiáng)直性脊柱炎患者的健康教育[A];第十屆全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2005年

3 沈友軒;周定華;王艷艷;柯瑤;王嬙;;強(qiáng)直性脊柱炎79例臨床特點(diǎn)分析[A];第十屆全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2005年

4 潘文友;劉焱;劉華;;晚發(fā)強(qiáng)直性脊柱炎十例分析[A];第十屆全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2005年

5 張麗穎;劉朋;;晚發(fā)強(qiáng)直性脊柱炎八例臨床分析[A];第十屆全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2005年

6 張自強(qiáng);方澤志;汪方記;;強(qiáng)直性脊柱炎證治附60例療效觀察[A];第十三屆全國(guó)中西醫(yī)結(jié)合骨傷科學(xué)術(shù)研討會(huì)論文集[C];2005年

7 卞曙曉;劉江濤;勾麗;劉興中;;強(qiáng)直性脊柱炎的早診斷早治療[A];中華醫(yī)學(xué)會(huì)疼痛學(xué)分會(huì)第六屆年會(huì)論文摘要[C];2005年

8 張秀英;董硯奉;國(guó)艷霞;焦紅梅;王麗;;強(qiáng)直性脊柱炎誤診24例分析[A];全國(guó)自身免疫性疾病專題研討會(huì)暨第十一次全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2006年

9 閻小萍;;強(qiáng)直性脊柱炎誤診131例分析[A];全國(guó)中西醫(yī)結(jié)合強(qiáng)直性脊柱炎專題研討會(huì)論文匯編[C];2007年

10 張育;王艷茹;馬瑩瑩;;強(qiáng)直性脊柱炎患者721例的臨床回顧分析[A];第17次全國(guó)風(fēng)濕病學(xué)學(xué)術(shù)會(huì)議論文集[C];2012年

相關(guān)重要報(bào)紙文章 前10條

1 中日友好醫(yī)院風(fēng)濕免疫科主任醫(yī)師 馬麗;強(qiáng)直性脊柱炎結(jié)成群害親人[N];保健時(shí)報(bào);2007年

2 南京軍區(qū)福州總醫(yī)院內(nèi)分泌科 馮修高 整理 吳志 張文明;肺炎衣原體可引發(fā)強(qiáng)直性脊柱炎[N];健康報(bào);2013年

3 中華醫(yī)學(xué)會(huì)風(fēng)濕病學(xué)分會(huì)候任主任委員 北京協(xié)和醫(yī)院風(fēng)濕科主任醫(yī)師 曾小峰;強(qiáng)直性脊柱炎能被有效控制[N];光明日?qǐng)?bào);2013年

4 本報(bào)記者 姜晨怡;強(qiáng)直性脊柱炎 易被誤診的“不死癌癥”[N];科技日?qǐng)?bào);2013年

5 本報(bào)記者 熊昌彪;治療強(qiáng)直性脊柱炎要走出兩個(gè)誤區(qū)[N];中國(guó)醫(yī)藥報(bào);2013年

6 馮興華;中醫(yī)治療強(qiáng)直性脊柱炎[N];健康報(bào);2003年

7 ;強(qiáng)直性脊柱炎及早治療是關(guān)鍵[N];上�？萍紙�(bào);2002年

8 石蘭;強(qiáng)直性脊柱炎的康復(fù)護(hù)理[N];醫(yī)藥養(yǎng)生保健報(bào);2005年

9 劉秀鳳;強(qiáng)直性脊柱炎的康復(fù)運(yùn)動(dòng)[N];醫(yī)藥養(yǎng)生保健報(bào);2005年

10 周武;強(qiáng)直性脊柱炎為何易誤診？[N];浙江日?qǐng)?bào);2003年

相關(guān)博士學(xué)位論文 前10條

1 管明強(qiáng);強(qiáng)直性脊柱炎診療現(xiàn)狀的臨床研究[D];南方醫(yī)科大學(xué);2014年

2 趙英華;磁共振成像對(duì)強(qiáng)直性脊柱炎骶髂關(guān)節(jié)炎活動(dòng)性的檢測(cè)[D];南方醫(yī)科大學(xué);2015年

3 劉軍;ANO6,HAPLN1,EDIL3在中國(guó)漢族人群中與強(qiáng)直性脊柱炎的易感性及嚴(yán)重程度的相關(guān)性的研究[D];天津醫(yī)科大學(xué);2015年

4 陳猛;調(diào)節(jié)性B細(xì)胞在強(qiáng)直性脊柱炎（Ankylosing spondylitis AS）患者中的分布及功能[D];山東大學(xué);2016年

5 周穎燕;補(bǔ)腎強(qiáng)督法治療強(qiáng)直性脊柱炎的療效及抗骨化作用初探[D];廣州中醫(yī)藥大學(xué);2016年

6 張虎;強(qiáng)直性脊柱炎關(guān)節(jié)滑膜高表達(dá)碳酸酐酶1[D];山東大學(xué);2011年

7 朱洪民;強(qiáng)直性脊柱炎早期診斷的臨床研究[D];南方醫(yī)科大學(xué);2011年

8 葉玲英;新型調(diào)節(jié)性T細(xì)胞在強(qiáng)直性脊柱炎患者中的作用研究[D];第二軍醫(yī)大學(xué);2013年

9 謝偉林;強(qiáng)直性脊柱炎發(fā)病的免疫遺傳機(jī)制及風(fēng)險(xiǎn)預(yù)報(bào)研究[D];第二軍醫(yī)大學(xué);2012年

10 陳蕊雯;中國(guó)漢族人群強(qiáng)直性脊柱炎候選基因的研究[D];第二軍醫(yī)大學(xué);2005年

相關(guān)碩士學(xué)位論文 前10條

1 袁躍興;強(qiáng)直性脊柱炎患者血清IL-23、IFN-γ的表達(dá)水平及臨床意義[D];福建醫(yī)科大學(xué);2015年

2 王剛;強(qiáng)直性脊柱炎的診斷與治療相關(guān)研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

3 楊帆;TNF-α拮抗劑與傳統(tǒng)藥物相比對(duì)全髖關(guān)節(jié)置換術(shù)后強(qiáng)直性脊柱炎患者關(guān)節(jié)功能影響的研究[D];中國(guó)人民解放軍醫(yī)學(xué)院;2015年

4 張應(yīng)子;強(qiáng)直性脊柱炎STAT3表達(dá)及其與治療的相關(guān)性研究[D];蘇州大學(xué);2015年

5 胡艷婷;強(qiáng)直性脊柱炎患者主觀幸福感現(xiàn)狀及影響因素分析[D];安徽醫(yī)科大學(xué);2015年

6 范大志;IL-33基因單核苷酸多態(tài)性與強(qiáng)直性脊柱炎遺傳易感性的關(guān)聯(lián)分析[D];安徽醫(yī)科大學(xué);2015年

7 劉麗;強(qiáng)直性脊柱炎（AS）患者外周血單個(gè)核細(xì)胞中miRNAs的表達(dá)與血清細(xì)胞因子相關(guān)性研究[D];安徽醫(yī)科大學(xué);2015年

8 徐立偉;祛瘀舒督顆粒治療強(qiáng)直性脊柱炎臨床觀察[D];中國(guó)中醫(yī)科學(xué)院;2015年

9 李亭;活動(dòng)期強(qiáng)直性脊柱炎骶髂關(guān)節(jié)的磁共振擴(kuò)散加權(quán)成像研究[D];山西醫(yī)科大學(xué);2015年

10 焦蕊蕊;實(shí)時(shí)超聲彈性成像對(duì)強(qiáng)直性脊柱炎患者跟腱損傷的評(píng)估價(jià)值[D];山西醫(yī)科大學(xué);2015年

，

本文編號(hào)：2174327